Biopharma Quarterly Deal Statistics, Q1 2012
A look at financing, M&A, and alliance activity January–March 2012
Executive Summary
Biopharma financing totaled $3.7 billion in Q1 2012, $1 billion more than the previous quarter. A total of 22 M&As – with a potential value of $9.28 billion – were completed. Acquisitions of private biotechs structured with earn-outs were a highlight. About a quarter of the alliances involved Big Pharmas, with GlaxoSmithKline and Novartis taking the lead.